BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BC Week In Review | Jan 18, 2019
Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
BC Extra | Jan 16, 2019
Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
BC Week In Review | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
BC Innovations | Jan 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest IFNB1 could help treat breast cancer. In breast tissue samples from patients with invasive ductal carcinoma, levels of IFNB1 were higher in tumors than in...
BC Extra | Aug 17, 2017
Politics & Policy

Representatives investigating rising MS prices

Reps. Elijah Cummings (D-Md.) and Peter Welch (D-Vt.) launched an investigation into the rising price of multiple sclerosis drugs, citing increases in price of as much as 1002% over the lifetime of a drug despite...
BioCentury | Aug 17, 2015
Strategy

Shifting MS spending

Payers are finally getting - and using - the tools to end uninterrupted price increases for multiple sclerosis drugs as a result of an abundance of options, greater willingness to steer prescribing choices, and the entrance of...
BC Extra | Apr 25, 2015
Financial News

Pfenex raises $40.5 million in follow-on

Pfenex Inc. (NYSE-M:PFNX) raised $40.5 million through the sale of 2.6 million shares at $15.50 in a follow-on underwritten by Barclays; Evercore; and William Blair. Existing stockholders also sold 3.4 million shares in the offering....
BioCentury | Sep 1, 2014
Strategy

Back to School: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
Items per page:
1 - 10 of 248